JT already has obtained manufacturing and marketing approval for Riona which is being distributed by Torii as a treatment for improvement of hyperphosphatemia in patients with chronic kidney disease in
Starting today,
JT, Torii and ASKA expect Riona to be a new option to help patients with IDA in
Outline of approval
Product
Indications: Improvement of hyperphosphatemia in patients with chronic kidney disease, Iron Deficiency Anemia
Dosage and Administration
For improvement of hyperphosphatemia in patients with chronic kidney disease; The recommended starting dose for adult patients starts at 500 mg of ferric citrate taken orally three times daily immediately after meals. Thereafter, the dose should be adjusted as appropriate depending on the degree of symptoms and serum phosphorus concentration. The maximum daily dosage is 6,000 mg.
For patients with iron deficiency anemia; The usual adult dosage for oral use begins at 500 mg of ferric citrate once daily immediately after meals. Thereafter, the dosage should be adjusted based on the degree of symptoms. The maximum dosage is 500 mg twice daily.
ABOUT Riona Tablets 250mg
'Riona Tablets 250mg' is approved and marketed for the treatment of hyperphosphatemia in adult patients with chronic kidney disease (CKD) both on dialysis and not on dialysis in
In
ABOUT Iron Deficiency Anemia (IDA)
IDA is the most frequent anemia, which is caused by decreasing hemoglobin production due to iron deficiency. IDA involves symptoms of anemia with palpitations and shortness of breath, as well as pica, fatigability, etc., which can lead to the decrease in the patient's quality of life. Treatments for IDA include the iron supplementation and the correction of underlying cause.
Contact:
Tel: +81-3-6636-2026
Email: jt.media.relations@jt.com
(C) 2021 Electronic News Publishing, source